MedPath

Posaconazole

Generic Name
Posaconazole
Brand Names
Noxafil, Posanol, Posaconazole Accord, Posaconazole AHCL
Drug Type
Small Molecule
Chemical Formula
C37H42F2N8O4
CAS Number
171228-49-2
Unique Ingredient Identifier
6TK1G07BHZ

Overview

Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

Background

Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

Indication

For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.

Associated Conditions

  • Candidiasis
  • Coccidioidomycosis
  • Esophageal Candidiasis
  • Fungal Infections
  • Invasive Aspergillosis
  • Invasive bronchopulmonary aspergillosis
  • Mucormycosis
  • Oropharyngeal Candidiasis
  • Prophylaxis of Aspergillus infection
  • Pulmonary cryptococcosis infection

FDA Approved Products

POSACONAZOLE
Manufacturer:ATLANTIC BIOLOGICALS CORP.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2022/03/01
NDC:17856-2133
Posaconazole
Manufacturer:American Health Packaging
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/09/25
NDC:60687-523
POSACONAZOLE
Manufacturer:NorthStar RxLLC
Route:ORAL
Strength:100 mg in 1 1
Approved: 2021/07/20
NDC:16714-156
Posaconazole
Manufacturer:Amneal Pharmaceuticals NY LLC
Route:ORAL
Strength:100 mg in 1 1
Approved: 2022/09/22
NDC:69238-1476
POSACONAZOLE
Manufacturer:Eugia US LLC
Route:INTRAVENOUS
Strength:18 mg in 1 mL
Approved: 2022/04/20
NDC:55150-388

Singapore Approved Products

POSACONAZOLE SANDOZ GASTRO-RESISTANT TABLETS 100MG
Manufacturer:Catalent Pharma Solutions LLC, Lek Pharmaceuticals d.d. (Primary and Secondary Packager)
Form:TABLET, DELAYED RELEASE
Strength:100.00 mg
Online:Yes
Approved: 2020/03/09
Approval:SIN15897P
NOXAFIL TABLET 100MG
Manufacturer:N. V. Organon
Form:TABLET, DELAYED RELEASE
Strength:100mg
Online:Yes
Approved: 2016/07/05
Approval:SIN15045P
NOXAFIL ORAL SUSPENSION 40 mg/ml
Manufacturer:Patheon Inc.
Form:SUSPENSION
Strength:40mg/ml
Online:Yes
Approved: 2009/05/25
Approval:SIN13654P
SINOTRX POSACONAZOLE DELAYED RELEASE TABLET 100MG
Manufacturer:HAIMEN PHARMA INC
Form:TABLET, DELAYED RELEASE
Strength:100 mg
Online:Yes
Approved: 2022/04/13
Approval:SIN16477P
POSATIF POSACONAZOLE GASTRO-RESISTANT TABLETS 100MG
Manufacturer:AET Laboratories Pvt. Ltd
Form:TABLET, DELAYED RELEASE
Strength:100 mg
Online:Yes
Approved: 2025/03/10
Approval:SIN17200P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath